SAB Biotherapeutics, Inc. (SABS) News
Follow SAB Biotherapeutics, Inc. (SABS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
SAB Biotherapeutics Reports Third-Quarter 2026 Loss
SAB Biotherapeutics reported no revenue in the quarter, unchanged from a year earlier, and swung to a loss from income. The headline reports EPS of ($0.24).
EQUITY | Nov 05, 2026, 12:42 PM UTC
M
SAB BIO Reports Q3 2026 Financial Results and Business Highlights
Adult and adolescent cohorts are fully enrolled in the registrational SAFEGUARD study of SAB-142.
EQUITY | Nov 05, 2026, 12:30 PM UTC
M
SAB Biotherapeutics to Host Q3 2026 Results Call November 5
SAB Biotherapeutics said it will host its third-quarter 2026 financial results conference call and webcast on November 5, 2026, at 8:30 a.m. ET.
EQUITY | Oct 29, 2026, 12:37 PM UTC
L
SABS pivotal study for SAB-142 advances; enrollment due Q4 2026
SafetyGUARD pivotal study for SAB-142 is on track, with last patient enrollment expected in Q4 2026 and top-line data in the second half of 2027. The company says it is funded through 2028.
MACRO | Sep 10, 2026, 04:41 PM UTC
L
SAB Biotherapeutics to take part in upcoming investor conferences
SAB Biotherapeutics, Inc. (Nasdaq: SABS) said members of its management team will participate in upcoming investor conferences.
EQUITY | Sep 01, 2026, 12:37 PM UTC
M
SABS: Barclays Initiates Overweight
Barclays initiates coverage on SAB Biotherapeutics with an Overweight rating and a price target of $13
EQUITY | Jun 24, 2026, 06:50 PM UTC